文献速递临床试验与 GCP基础与转化研究

机械取栓联合抗凝与单纯抗凝治疗急性中高危肺栓塞的随机对照试验方案(CAPE研究)

Effects of mechanical thrombectomy combined with anticoagulation vs anticoagulation monotherapy for acute intermediate-high risk pulmonary embolism: study protocol for a randomized controlled trial (CAPE study, ChiCTR2500095253, https://www.medicalresearch.org.cn/clinicalResearch/researchInfo?id=c57630b7-51ec-4b24-83e1-85b9c0a835d6).
PubMed 文献 · Trials · 2026-08-04

CAPE研究是一项正在入组的全国多中心随机对照试验,计划纳入156例急性中高危肺栓塞患者,按1:1随机分配至机械取栓联合抗凝组或单纯抗凝组。主要疗效终点为48小时CTPA评估的右心室/左心室直径比降低,主要安全终点为3个月内严重不良事件。该研究旨在比较两种策略的短期和长期疗效,为临床决策提供更多证据,尤其针对亚洲人群。

要点

  • CAPE研究比较机械取栓联合抗凝与单纯抗凝治疗急性中高危肺栓塞的疗效与安全性。
  • 主要疗效终点为48小时CTPA评估的RV/LV直径比降低,主要安全终点为3个月内严重不良事件。
  • 研究计划纳入156例患者,按1:1随机分组,目前正在入组。

核心结论

  • 机械取栓联合抗凝是否优于单纯抗凝尚需更多证据,尤其缺乏亚洲人群数据,CAPE研究旨在填补这一空白。

研究设计与样本

  • CAPE研究为正在入组的全国多中心随机对照试验,计划纳入156例急性中高危肺栓塞患者,按1:1随机分配至机械取栓联合抗凝组或单纯抗凝组。
  • 患者按最新欧洲心脏病学会指南分类标准进行分层。
  • 机械取栓使用MPA 8F指引导管(Cordis(上海)医疗器械有限公司)。

主要发现

  • STORM-PE试验显示,与单纯抗凝相比,机械取栓联合抗凝在48小时显著降低RV/LV直径比,两组主要不良事件发生率均较低。
  • 近期研究显示,与导管定向溶栓相比,机械取栓的临床恶化或补救治疗及术后ICU使用率更低,死亡率和出血无差异。

关键数值与推荐

  • 主要疗效终点为48小时CTPA评估的RV/LV直径比降低。
  • 次要疗效终点为慢性血栓栓塞性肺疾病(包括慢性血栓栓塞性肺动脉高压)的发生率。
  • 主要安全终点为至3个月随访的严重不良事件(包括大出血)。

临床怎么用

  • 研究结果将为医生选择急性中高危肺栓塞的不同治疗策略提供更多证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment of intermediate-high-risk pulmonary embolism is still debated. Interventional therapy is being increasingly widely applied in clinical practice. Numerous studies have confirmed that interventional therapy is effective. Both catheter-directed thrombolysis (CDT) and mechanical thrombectomy (MT) showed improvement in some efficacy outcomes compared with anticoagulation monotherapy. A recent study showed that MT has lower rates of clinical deterioration and/or bailout and postprocedural intensive care unit use compared with CDT, with no difference in mortality or bleeding, which makes the application of MT in clinical practice increasingly widespread. Recently, STORM-PE, the first randomized controlled trial to test the efficacy and evaluate the safety of MT combined with anticoagulation compared with anticoagulation monotherapy for the treatment of intermediate-high-risk pulmonary embolism, showed that treatment with MT combined with anticoagulation resulted in a significantly greater reduction in right ventricular/left ventricular (RV/LV) diameter ratio at 48 h versus anticoagulation monotherapy, with comparably low rates of major adverse events in both treatment arms. However, whether MT combined with anticoagulation is more effective than anticoagulation monotherapy needs more evidence, especially in Asian populations. METHODS: The CAPE study is a currently enrolling national multicenter randomized controlled trial (RCT) comparing MT with MPA 8F guiding catheter [Cordis (Shanghai) Medical Device Co., Ltd] combined with anticoagulation vs anticoagulation monotherapy. A total of 156 patients with acute intermediate-high-risk pulmonary embolism stratified by the classification of the latest guideline of European Society of Cardiology (ESC) will be enrolled and randomized in a 1:1 ratio. The primary efficacy endpoint was reduction of RV/LV diameter ratio assessed by computed tomographic angiography (CTPA) at 48 h. The secondary efficacy endpoint was the incidence of chronic thromboembolic pulmonary disease including chronic thromboembolic pulmonary hypertension. The primary safety endpoint was serious adverse events including major bleeding through 3 months visit. DISCUSSION: CAPE is a RCT to compare the short and long efficacy of MT combined with anticoagulation and anticoagulation monotherapy for acute intermediate-high pulmonary embolism. The result will give more evidence for selection of different strategies for physicians. TRIAL REGISTRATION: CAPE study is registered in Chinese Clinical Trial Registry identifier (ChiCTR2500095253, https://www.medicalresearch.org.cn/clinicalResearch/researchInfo?id=c57630b7-51ec-4b24-83e1-85b9c0a835d6 ). Registered on November 26 2024.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Huang Q, Feng L, Liu L, et al. Effects of mechanical thrombectomy combined with anticoagulation vs anticoagulation monotherapy for acute intermediate-high risk pulmonary embolism: study protocol for a randomized controlled trial (CAPE study, ChiCTR2500095253, https://www.medicalresearch.org.cn/clinicalResearch/researchInfo?id=c57630b7-51ec-4b24-83e1-85b9c0a835d6). Trials. 2026. PMID: 42958300. doi:10.1186/s13063-026-09932-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。